Celgene Corp (CELG) Return on Investment ROI from the third quarter of 2019 to third quarter of 2018 and for the year 2019, average high and low, overall ranking from Sep 30 2019 to Sep 30 2018 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Celgene Corp  (NASDAQ: CELG)


Celgene's ROI from its third quarter of 2019 to the third quarter of 2018 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Celgene's ROI in the third quarter of 2019?
Celgene Corp achieved a return on average invested assets (ROI) of 16.83 % in its third quarter of 2019, this is above CELG's average return on investment of 6.17%.
Celgene Corps investments during the 12 months ending in the third quarter of 2019 are valued at $34 billion

ROI has improved compared to 15.75% in the second quarter of 2019, due to net income growth.

Within the Healthcare sector 146 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2019 from 1186 to 1627.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter		 (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter
Y / Y Investment Change TTM 18.33 % 26.66 % 33.25 % 50.61 % 50.38 %
Y / Y Net Income Change TTM 103.32 % 88.38 % 170.68 % 346.09 % 192.71 %
Investment (TTM) in Millions 36,354 35,498 33,684 34,176 30,532
Return On Investment (TTM) 16.83 % 15.75 % 14.91 % 12.94 % 9.8 %
CELG's Overall Ranking # 1627 # 1186 # 1579 # 0 # 0
Seq. Investment Change TTM 4.35 % 5.15 % 1.79 % 5.95 % 11.69 %
Seq. Net Income Change TTM 11.55 % 11.09 % 17.28 % 39.9 % 3.36 %
Net Income (TTM) in Millions 5,880 5,271 4,745 4,046 2,892

CELG Company Profile >> Back to CELG Roi Comparisons >> See Annual CELG Return On Investment



Return On Investment CELG's Ranking
Within: No.
Industry # 54
Sector # 147
Overall # 1627

Return On Investment Statistics
High Average Low
22.92 %
6.17 %
-49.9 %
(Dec. 31, 2005)   (March 31, 2008)







Financial Statements
Celgene's III. Quarter Investments $ 36,354 Millions CELG's Balance sheet
Celgene's III. Quarter Income $ 1,691 Millions Quarterly CELG's Income Statement
CELG's Income by Division See CELG's Income by Division


CELG Annual Return On Investment (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015		 (FY 2014)
(Dec. 31, 2014)
Total Investments in Millions 31,423 27,154 22,607 22,565 15,228
Y / Y Investment Growth 15.72 % 20.11 % 0.19 % 48.18 % 33.2 %
Net Income in Millions 4,046 2,940 1,999 1,602 2,000
Y / Y Net Income Growth 37.62 % 47.06 % 24.79 % -19.9 % 37.93 %
Annual Return On Investment 12.88 % 10.83 % 8.84 % 7.1 % 13.13 %


Annual Roi Comment
In the fiscal year 2018 ROI improved to 12.88 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CELG's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CELG's Competitors
Subscribers only: Roi for Celgene's Suppliers
Subscribers only: Return On Investment for CELG's Customers

Other Ratios
CELG's Roa CELG's Inventory Turnover Ratio CELG's Growth Rates CELG's Dividend Statistics
CELG's Profitability Ratios CELG's Asset Turnover Ratio CELG's Dividend Growth
CELG's Roe CELG's Valuation Ratios CELG's Financial Strength Ratios CELG's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2019, within Healthcare Sector ROI
Castle Biosciences Inc   42.65 %
Remedent Inc   42.49 %
Exelixis Inc   41.45 %
Ligand Pharmaceuticals Incorporated  38.90 %
Oramed Pharmaceuticals Inc  37.93 %
Vanda Pharmaceuticals Inc   37.58 %
Vertex Pharmaceuticals Inc  36.81 %
Strongbridge Biopharma plc  34.65 %
Harrow Inc   32.26 %
Arrowhead Pharmaceuticals Inc   31.44 %
Align Technology inc   30.40 %
Lifevantage Corp  29.12 %
Corcept Therapeutics Inc  29.06 %
Eli Lilly And Company  28.71 %
Mettler toledo International Inc   28.61 %
Fonar Corporation  28.43 %
Idexx Laboratories Inc  27.80 %
Siga Technologies Inc  25.81 %
Integrated Biopharma Inc  25.06 %
Biogen Inc   24.67 %
Chemed Corporation  23.93 %
Abiomed Inc   22.95 %
Biospecifics Technologies Corp  22.30 %
Alpha Pro Tech Ltd   20.98 %
Viemed Healthcare Inc   20.89 %
Regeneron Pharmaceuticals Inc   18.65 %
Pro dex Inc   18.42 %
Amgen Inc   18.22 %
Contrafect Corporation  17.96 %
Masimo Corp  17.60 %

Date modified: 2026-09-08T15:09:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.